STE Stock Recent News

STE rides on strong Healthcare and AST growth, but macro pressures and customer consolidation cloud its outlook.

Investing in growth stocks is a proven way to increase your investment portfolio over the long term. By parking available funds, say $5,000, in strong, growing companies, and keeping it there long-term, you are likely to see the value of those investments rise steadily, generating the funds you need to finance your future lifestyle.

Steris (STE) reported earnings 30 days ago. What's next for the stock?

STE frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses.

STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.

Dublin, May 20, 2025 (GLOBE NEWSWIRE) -- The "U.S. Gynecological Chairs and Tables Market Size, Share & Trends Analysis Report by Product (Gynecological Chairs, Gynecological Tables), Application (Urology Surgery, Pelvic Surgery), End-use, with Growth Forecasts, 2025-2030" report has been added to ResearchAndMarkets.com's offering. The U.S. Gynecological Chairs and Tables Market was valued at USD 194.8 Million in 2024, and is projected to reach USD 283.8 Million by 2030, rising at a CAGR of 6.50%.

Examine Steris' (STE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Steris plc remains a Strong Buy with a fair value of $281, supported by robust organic growth and margin expansion. The Trump administration's push to reshore pharma manufacturing could be a major tailwind for Steris's AST business. Steris's balanced growth in pricing and volume, along with cost initiatives, positions it for continued operating margin improvement.

STERIS plc (NYSE:STE ) Q4 2025 Results Conference Call May 15, 2025 9:00 AM ET Company Participants Julie Winter - Investor Relations Mike Tokich - Senior Vice President and Chief Financial Officer Dan Carestio - President and Chief Executive Officer Conference Call Participants Dave Turkaly - Citizens Mike Matson - Needham & Company Patrick Wood - Morgan Stanley Mac Etoch - Stephens, Inc Michael Polark - Wolfe Research Jason Bednar - Piper Sandler Brett Fishbin - KeyBanc Operator Good morning, everyone, and welcome to the STERIS plc Fourth Quarter 2025 Conference Call. All participants will be in a listen-only mode.

STERIS' fourth-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues.